Table II Sample Clauses

Table II. Item Loadings for a PCA with FS and FA Items with Data from Wave 1 Component 1 Component 2 FSSoM1 .84 FSSoM2 .62 FSSoM3 .83 FSFRW1 .90 FSFRW2 .82 FSFRW3 .87 FSSTF1 .59 FSSTF2 .76 FSSTF3 .34 FSLoC1 .57 FSLoC2 FSLoC3 .80 .43 FADFD1 .83 FADFD2 .87 FADFD3 .84 FADFD4 .67 FAAFI1 .57 FAAFI2 .58 .32 FAAFI3 .58 FAAFI4 .54

Table II. We hereby certify to you as follows:

Table II. Objective and subjective voice frequency and virilizing adverse events per dosage group. GH+Pl GH+Ox GH+Ox GH+Ox 0.06 GH+Ox (N = 30) 0.03 0.03 vs. (N = 27) 0.06 vs. Outcome (N = 31) GH+Pl GH+Pl P Value P Value Voice frequency at starting Ox/Pl (all age groups) – SDS†‡ Age group 1 (after previous GH therapy) – SDS† 1.1±1.2** 0.6±1.2 0.9±1.4** 0.4±1.6 1.0±0.9** 1.0±1.0 Age groups 2 and 3 (at baseline) – SDS† 1.2±1.2** 1.1±1.4** 1.0±0.9** Change in voice frequency during Ox/Pl (all age groups) – SDS/yr, SE§ -0.05, 0.05 -0.17, 0.05 0.09 -0.27, 0.06 0.007 Age group 1 (after previous GH therapy) – SDS/yr, SE -0.02, 0.08 -0.13, 0.09 0.3 -0.29, 0.10 0.04 Age groups 2 and 3 – SDS/yr, SE -0.06, 0.07 -0.21, 0.06 0.1 -0.22, 0.09 0.2 Change in voice frequency during Ox/Pl without outliers – SDS/yr, SE¶ -0.07, 0.05 -0.16, 0.05 0.2 -0.26, 0.06 0.02 Voice frequency at the last measurement – SDS 0.6±0.7** 0.3±1.2 0.4 -0.2±1.6 0.06 Girls reporting subjective voice deepening – n (%) 10 (33%) 13 (42%) 0.5 14 (52%) 0.2 Girls reporting virilization other than voice deepening during Ox/Pl – n (%)║ 1 (3%) 5 (16%) 0.2 8 (30%) 0.01 Hirsutism 1 (3%) 4 (13%) 0.4 8 (30%) 0.01 Mild clitoromegaly 0 (0%) 4 (13%) 0.1 4 (15%) 0.04 * values are expressed as means±SD, unless otherwise indicated. † No statistical tests were applied to assess differences between the dosage groups at starting Ox/Pl. ‡ Based on 18, 19 and 11 tests in GH+Pl, GH+Ox 0.03 and GH+Ox 0.06, respectively. These recordings were included in repeated measurements analyses, which takes into account missing data. § Based on 123, 149 and 92 tests during Ox/Pl and 20, 26, 21 tests at the last measurement (i.e. at or after discontinuation of Ox/Pl) in GH+Pl, GH+Ox 0.03 and GH+Ox 0.06, respectively. ¶ Five voice recordings (of two girls) that displayed a voice frequency higher than 4.5 SDS were identiefied as outliers. ║ Some patients reported hirsutism as well as clitoromegaly, while others reported only one these complaints. The number of the patients reporting both adverse event may therefore not equal the numbers in this row. ** Significantly different from 0 SDS (i.e. from healthy Dutch girls, P<0.05). GH+Pl GH+Ox 0.03 GH+Ox 0.06 60 50 % of patients 40 10 0 voice voice breaks hoarseness voice has voice has voice has nasal sound deepening become become become softer higher louder

Table II. Additional information and criteria of qualitative studies applicable to our study, based on the COREQ checklist (Tong, Sainsbury, & Xxxxx, 2007) Domains and items Description

Table II. Supervisor Allowance Xxx Xxxxx Effective until June 9, 2022 $6,611 Effective June 10, 2022, 0.50% Increase $6,644 Effective September 1, 2022, 1.25% Increase $6,727 Effective September 1, 2023, 2.00% Increase $6,862

Table II. Tri-Town Budgets FY'2006-2012 Tri-Town Proportional Sharing Analysis (Mileage Tri-Town Proportional Sharing Analysis (Mileage Tri-Town Proportional Sharing Analysis (Calls) Tri-Town Proportional Sharing Analysis (Calls)

Table II. Lifetime Cumulative Unit Sales Per Percentage decrease of License Fee Product -------------------------------------------------------------------------------- 50,000 - 99,999 5% -------------------------------------------------------------------------------- 100 000 - 199.999 10% -------------------------------------------------------------------------------- 150,000 plus 15% --------------------------------------------------------------------------------

Table II. Portfolio Guidelines Min Wtd Sub- Sub-Portfolio Concentration Limits Avg Investment Portfolio Max Portfolio Sub- Instrument Yield Duration Per Issue Sub-Portfolio Quality Portfolio Max Benchmarks Name (Note 3) Max (Notes 1 & 2) Maturity MMFs N/A Up to 100% USTs 1 year Up to 100% none USAs 1 year Up to 75% Repos 7 days Up to 50% Enhanced Note 4 N/A CDs 1 year Up to 25% Cash CCP or 1 year 5% or less of Up to 75% MCP sub-portfolio Corps 1 year Up to 25% Munis 1 year Up to 100% BAML 1-3 USTs Up to 100% Year USAs none Up to 75% Treasury MFs Up to 100% Short Index SOVs Up to 25% Duration or 2 years AA-/ MRS N/A Up to 25% Aa3/AA- (~1-3 yr Barclays or less maturities) Capital 1 ABS 5% or less of Up to 25% Year Corps sub-portfolio Up to 25% Municipal Munis Up to 100% Bond Index BAML 1-3 USTs Up to 100% Year USAs none Up to 75% Treasury MFs Up to 100% Intermediate Index SOVs Up to 25% Duration or 4 years MRS N/A Up to 25% (~4-7 yr Barclays or less maturities) Capital 5 ABS 5% or less of Up to 25% Year Corps sub-portfolio Up to 25% Municipal Munis Up to 100% Bond Index 1. Initial Quality: At the time of purchase, no more than 10% of the securities in a sub-portfolio may be rated A- /A3/A- or less. Also at the time of purchase, no more than 5% of the securities in a sub-portfolio may be unrated.

Table II. Table II specifies the protection criteria for UHF assignments whose parameters exceed 1000 kW ERP and/or 300 metres EHAAT.

Table II. Interlistener agreement: mean difference (standard error) between a listener’s rating of a speaker and another listener’s rating of that speaker for unanchored (U) and anchored (A) protocols. R = rough, B